BioCentury
ARTICLE | Clinical News

Amitifadine: Phase IIb/IIIa data

June 3, 2013 7:00 AM UTC

Top-line data from the double-blind, U.S. Phase IIb/IIIa TRIADE trial in 342 patients with MDD showed that once-daily 50 and 100 mg doses of amitifadine each missed the primary endpoint of improving M...